Professional Documents
Culture Documents
Copia para uso personal, se prohbe la transmisin de este documento por cualquier medio o formato.
www.elsevier.es/medicinaclinica
Editorial
N D E L A R T I C U L O
INFORMACIO
Documento descargado de http://www.elsevier.es el 20/08/2016. Copia para uso personal, se prohbe la transmisin de este documento por cualquier medio o formato.
309
os
de animales. Esta vacuna fue administrada a cerca de 100.000 nin
os 1973 y 1976 sin que se pudieran detectar
durante los an
complicaciones o efectos adversos importantes16.
Un estudio reciente de Saito et al17 ha analizado la respuesta
Documento descargado de http://www.elsevier.es el 20/08/2016. Copia para uso personal, se prohbe la transmisin de este documento por cualquier medio o formato.
310
os? La
evolucion biologica natural a lo largo de millones de an
asamblea general de la OMS que se celebrara en mayo de 2011
volvera a debatir los pros y contras del almacenamiento, utilizacion
o destruccion de las cepas oficialmente conservadas en los dos
centros colaboradores. Deberemos esperar a esta reunion para
conocer el futuro definitivo, probablemente se establezca una
nueva moratoria, de las ultimas cepas del virus de la viruela.
Bibliografa
1. Reina Prieto J, Vidal Verdu E. Infecciones por Poxvirus. En: Ausina Ruiz, V,
Moreno Guillen S, editors. Tratado SEIMC de Enfermedades Infecciosas y
Microbiologa Clnica. Captulo 76. Madrid: Editorial Panamericana-SEIMC;
2006. p. 72530.
2. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication.
Geneva: World Health Organization; 1988. p. 1340.
3. Tucker JB. Breaking the deadlock over destruction of the smallpox virus stocks.
Biosecur Bioterror. 2011;9:5567.
4. Mahy BW, Almond JW, Berns KI, Channock RM, Lvov DK, Pettersson RF, et al. The
remaining stocks of smallpox virus should be destroyed. Science. 1993;262:
12234.
5. World Health Organization. Smallpox eradication: destruction of variola virus
stocks. A52.A/Conference Paper No. 1, May 20, 1999.
6. World Health Organization. Smallpox eradication: destruction of variola virus
stocks. Weekly Epidemiol Rec. 2002;77:348.
7. Hammond E; for Third World Network. Update on smallpox (variola) virus
destruction. 63rd WHO Assembly. Geneva, Switzerland 17-21 May 2010. p. 6-7.
8. World Health Organization. Major review of variola virus research, 1999-2010
[consultado 29/12/2010]. Disponible en: http://www.who.int/csr/disease/
smallpox/major_review/en/index.html
9. Henderson DA. Smallpox virus destruction and the implications of a new
vaccine. Biosecur Bioterror. 2011;9:16.
10. Monath TP, Caldwell JR, Mundt W, Fusco J, Johnson CS, Buller M, et al.
ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of
Health strain)-a second-generation smallpox vaccine for biological defense. Int
J Infect Dis. 2004;8 Suppl 2:S3144.
11. Weltzin R, Liu J, Pugachev KV, Myers GA, Coughlin B, Blum PS, et al. Clonal
vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med.
2003;9:112530.
12. Artenstein AW, Johnson C, Marbury TC, Morrison D, Blum PS, Kemp T, et al. A
novel, cell culture-derived smallpox vaccine in vaccinia-nave adults. Vaccine.
2005;23:33019.
13. Frey SE, Newman FK, Kennedy JS, Ennis F, Abate G, Hoft DF, et al. Comparison of
the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in
healthy vaccinia-naive adults. Vaccine. 2009;27:163744.
14. Centers for Disease Control. Update: cardiac and other adverse events following
civilian smallpox vaccination-United States. MMWR. 2003;52:6392.
15. Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M. LC16m8: an attenuated
smallpox vaccine. Vaccine. 2006;24:700922.
16. Yamaguchi M, Kimura M, Hirayama M. Vaccination research groups research
report: Ministry of Health and Welfare special research: postvaccination side
effects and research regarding treatment of complications. Rinsho To Uirusu.
1975;3:26979.
17. Saito T, Fujii T, Kanatani Y, Saijo M, Morikawa S, Yokote H, et al. Clinical and
immunological response to attenuated tissue-cultured smallpox vaccine
LC16m8. JAMA. 2009;301:102533.
18. Jones T. IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for
smallpox infection. Curr Opin Mol Ther. 2008;10:40717.
19. Kennedy JS, Greenberg RN. IMVAMUNE: modified vaccinia Ankara strain as an
attenuated smallpox vaccine. Expert Rev Vaccines. 2009;8:1324.
20. Von Krempelhuber A, Vollmar J, Pokorny R, Rapp P, Wulff N, Petzold B, et al. A
randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine. 2010;28:120916.
21. Parker S, Handley L, Buller RM. Therapeutic and prophylactic drugs to treat
orthopoxvirus infections. Future Virol. 2008;3:595612.
22. Weinstein RS, Weinstein MM, Alibek K, Bukrinsky MI, Brichacek B. Significantly
reduced CCR5-tropic HIV-1 replication in vitro in cells from subjects previously
immunized with vaccinia virus. BMC Immunol. 2010;11:23, doi: 10.1186/
1471-2172-11-23.
23. Weinstein RS. Should remaining stockpiles of smallpox virus (variola) be
destroyed? Emerg Infect Dis J. 2011;17:6813.